Share on LinkedInShare on LinkedIn

ARTICLE · 26 JANUARY 2024

Preventing Price Decreases Of Original Pharmaceutical Products With Partial Preliminary Injunctions

Gün + Partners
Gün + Partners
Contributor
Gün + Partners

Gün + Partners

We are one of the oldest and largest law firms in Turkey and are considered internationally to be...

View firm profile
Explore more from Gün + Partners

Taking the right steps at the right time, with the most appropriate strategy, is significantly important for patent owners of pharmaceutical products wishing to benefit...

TurkeyIntellectual Property

Taking the right steps at the right time, with the most appropriate strategy, is significantly important for patent owners of pharmaceutical products wishing to benefit from the related rights granted to them by the laws and international conventions. Indeed, the Turkish Industrial Property Code regulates the exception of patent rights concerning experimental acts in regard to the product subject to the invention, as well as marketing authorization, and the necessary testing and experiments within its scope. In practice, the Courts occasionally erroneously interpret the wording of the law in regards to this exception (known as the Bolar Exception), which leads to permitting applications to be made to the Social Security Institution (SSI) and even inclusion in the SSI reimbursement list. In such cases, the introduction of the generic pharmaceutical product to the market results in a decrease of 40% of the price of the original product and it is not always possible to

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from